Latest / The Dales Report | Trade to Black
What's Next for Psychedelic Leader Cybin in 2025? | TDR Small Cap Sunday
On our latest Small Cap Sunday podcast, we shift our attention to the psychedelics space to do a deep dive into industry leader Cybin (NYSE: CYBN). Cybin Inc., a leading psychedelic company, has had an eventful 2024. With partnerships with top research institutions, expansion of Phase 2 trials, and innovative drug formulations, Cybin is making strides in mental health therapeutics. Their current focus includes the Phase 3 PARADIGM™ program CYB003’for treating Major Depressive Disorder, a substantial market opportunity. The company's strong financial position, with a cash reserve of C$209…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.